Evidence map›Paper›PMID 33726848›Full record

ArticleInternational journal of retina and vitreous2021

The effects of age-related macular degeneration on quality of life in a Brazilian population.

Alicia Buffoni Roque, Géssica Fernandes da Silva Borges, Ricardo Yuji Abe, Osias Francisco de Souza, Maria Cecília Machado, Tamara Ferreira, Newton Kara José, José Paulo Cabral de Vasconcellos

Open access · goldAbstract read
In one paragraph

Article in International journal of retina and vitreous, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Quality of Life and Anxiety in Age Macular Degeneration Patients: A Cross-Sectional Study.International journal of environmental research and public health · 2022
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alicia Buffoni RoqueDepartment of Ophthalmology, Faculty of Medical Science, University of Campinas, Campinas, SP, Brazil. aliciabroque@gmail.com.ORCID https://orcid.org/0000-0002-0876-0675
Géssica Fernandes da Silva BorgesDepartment of Ophthalmology, Faculty of Medical Science, University of Campinas, Campinas, SP, Brazil.
Ricardo Yuji AbeDepartment of Ophthalmology, Faculty of Medical Science, University of Campinas, Campinas, SP, Brazil.
Osias Francisco de SouzaDepartment of Ophthalmology, Faculty of Medical Science, University of Campinas, Campinas, SP, Brazil.
Maria Cecília MachadoConderg-Divinolândia, Divinolândia, SP, Brazil.
Tamara FerreiraConderg-Divinolândia, Divinolândia, SP, Brazil.
Newton Kara JoséDepartment of Ophthalmology, Faculty of Medical Science, University of Campinas, Campinas, SP, Brazil.
José Paulo Cabral de VasconcellosDepartment of Ophthalmology, Faculty of Medical Science, University of Campinas, Campinas, SP, Brazil.
Universidade Estadual de Campinas (UNICAMP) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the impact of age-related macular degeneration (AMD) on the quality of life (QoL) in a Brazilian population using The National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25).

methodsThis observational study included 462 participants from the Departments of Ophthalmology of the University of Campinas and Conderg-Divinolândia. The NEI-VFQ-25 questionnaire and Rasch analysis were used to assess the vision-related quality of life (VRQoL). Patients with macular neovascularization were interviewed at enrollment and after three loading doses of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment.

resultsOne hundred thirty-three patients were excluded because they had another ophthalmic disease, for a total of 349 patients included in the study (177 in the AMD group, 172 in the control group; 56.4% were women; mean ± standard deviation age, 70.6 ± 9.5 years). Most NEI-VFQ-25 subscale scores were significantly lower in the AMD group compared with the control group. The Rasch-calibrated NEI-VFQ-25 median score in the visual-functioning component was 56.41 for the AMD group and 61.53 for the control group, a difference of ± 4.00 (P = 0.0001). Separate analyses of the sociodemographic and ocular characteristics showed that the NEI-VFQ-25 scores were affected mostly by family income, educational level, descent, diet (vegetables/fruits), physical activity, and visual acuity (VA). The longitudinal component assessed a different group of 48 patients with exudative disease treated with anti-VEGF drugs. The mean logarithm of the minimum angle of resolution change in VA in treated eyes was a 0.16 decrease (P = 0.01). The mean change in the optical coherence tomography macular thickness was a 36.74-μm decrease (P = 0.012) from baseline to 4 months. The mean NEI-VFQ-25 scores improved significantly from baseline to follow-up at 4 months in almost all subscales.

conclusionsIn a Brazilian community, patients with AMD had a worse VRQoL than controls. The AMD severity and bilaterality were associated with decreased NEI-VFQ-25 scores. Higher family income, educational level, descent, and lifestyle significantly improved several subscales of the NEI-VFQ-25 questionnaire. Treated patients with exudative AMD had improvements in the VA, macular thickness, and most NEI-VFQ-25 subscale scores.

Indexed as

Age-related macular degenerationQuality of lifeQuestionnaires

Identifiers

PMID33726848
PMCPMC7962216
OpenAlexW3136332188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.